Viridian Therapeutics Inc. Common Stock (VRDN)

FairStock Score: 38/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Looking at Viridian Therapeutics as a Graham-style bargain hunter, I see a clinical-stage biotech, not an operating business with durable earnings. It is developing IGF-1R and TSHR candidates for thyroid eye disease and Graves' disease. The science may be promising, but the financials show no moat I can underwrite. At the 2026-10-13 close of $18.22, market cap is about $2.1B. FairStock shows a negative P/E of -5.36, P/B 3.70, EPS -$3.40, ROE -65.74%, ROCE -30.16%, and a debt-to-equity ratio of 0.37. Trailing free cash flow is -$335.0M, a -16.2% FCF yield, so cash burn is the central fact. Filed results show why: in fiscal Q2 2026 revenue was only $284,000 and net loss was $127.1M; in fiscal Q1 2026 revenue was $141,000 and net loss was $104.9M. Fiscal 2025 revenue was $70.8M, helped by a $70.6M fiscal Q3 2025, but fiscal 2025 net loss was $342.6M. That revenue is uneven and not yet a recurring commercial base. Losses have widened from $237.7M in fiscal 2023 to $269.9M in fiscal 2024 and $342.6M in fiscal 2025. FairStock's 38/100 score, 4/9 Piotroski, and 1.58 Altman Z-score paint a fragile picture. The 52-week range of $13.18-$34.29 shows how sentiment-driven the shares are. Without profits or a proven product, intrinsic value rests on pipeline odds, not on present numbers. I would demand a much larger margin of safety before calling this a value investment.

In plain English: Viridian Therapeutics is a small healthcare company working on treatments for serious thyroid-related eye and autoimmune diseases. It has almost no regular sales yet and is losing large amounts of money, so the business looks weak on today’s numbers. At the recent close of $18.22, the stock looks expensive relative to the tiny revenue and losses, meaning most of its value depends on future drug success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer